we studied the efficacy and safety of recombinant interleukin-2 ( ril-2 : s-6820 ) for the treatment of renal cell carcinoma as well as the effect of blood transfusion upon the immune response of these patients .
C0021756
recombinant interleukin-2
C0301872
immune response